Clinical Trials Sponsored by Achillion, a wholly owned subsidiary of Alexion

Total 1006 results

Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Hepatitis C

United States, Belgium
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Human Immunodeficiency Virus (HIV)-1 Infection

United States, Spain, Germany, Dominican Republic
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Bulgaria, Former Yugoslavia
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

HIV Infections

United States, Puerto Rico
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Hepatitis C, Chronic

United States, Canada
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

HIV Infections

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

Chronic Hepatitis C Infection

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation (Resistance)

HIV Infections

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion
Achillion, a wholly owned subsidiary of Alexion

Terminated

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Chronic Hepatitis B

United States, Canada, China
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Radiolabeled Danicopan in Healthy Male Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

HCV Infection

United States, Germany, Netherlands
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Healthy | Renal Dysfunction

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Multiple Doses of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Celerion; Achillion, a wholly owned subsidiary of Alexion

Completed

A Drug Interaction Study of ACH-0145228

Healthy

United States
Alexion Pharmaceuticals
Celerion; Achillion, a wholly owned subsidiary of Alexion

Completed

A Drug Interaction Study of Danicopan

Healthy

United States
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, United States, Italy
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)

Terminated

Study Evaluating Betrixaban in Pediatric Participants

VTE Prophylaxis

United States, United Kingdom, Russian Federation, Ukraine
Reata, a wholly owned subsidiary of Biogen

Terminated

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE)

Chronic Kidney Diseases | Autosomal Dominant Polycystic Kidney | Alport Syndrome

United States, France, Australia, Japan, Spain, Puerto Rico
Reata, a wholly owned subsidiary of Biogen

Completed

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

Diabetic Nephropathy

United States
Reata, a wholly owned subsidiary of Biogen

Withdrawn

A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis

Type 2 Diabetes Mellitus | End-Stage Renal Disease
Reata, a wholly owned subsidiary of Biogen

Completed

RTA 408 Capsules in Patients With Melanoma - REVEAL

Melanoma | Unresectable (Stage III) Melanoma | Metastatic (Stage IV) Melanoma

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Human AME Study for Omaveloxolone

Healthy Male Subjects

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

Healthy Volunteers

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic

United States
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

Hypoglycemia

United Kingdom
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

Multiple Myeloma | Solid Tumours | Malignant Lymphomas | Chemotherapy-induced Symptomatic Anaemia

Germany
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Nivestim™ in Treatment of Malignant Diseases

Solid Tumour | Malignant Haematological Tumour | Primary or Secondary Prophylactic Treatment

Germany
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

Anesthesia | Surgical Procedures, Elective

United States
Hospira, now a wholly owned subsidiary of Pfizer

Terminated

Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

Pain | Cancer

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, United Kingdom, Australia, France, Japan, Germany, Belgium, Czechia, Italy
Reata, a wholly owned subsidiary of Biogen

Terminated

Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

United States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
Reata, a wholly owned subsidiary of Biogen

Terminated

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER (RANGER)

Pulmonary Hypertension

United States, Spain, Australia, United Kingdom, Canada, Belgium, Argentina, Israel, Japan, Philippines, Germany, Mexico, Brazil, Czechia, Netherlands
Reata, a wholly owned subsidiary of Biogen

Completed

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX (PHOENIX)

Focal Segmental Glomerulosclerosis | IgA Nephropathy | Autosomal Dominant Polycystic Kidney | CKD Associated With Type 1 Diabetes

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) (MERLIN)

Chronic Kidney Diseases

United States
Reata, a wholly owned subsidiary of Biogen

Completed

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Idiopathic Pulmonary Fibrosis | Pulmonary Arterial Hypertension | Pulmonary Hypertension | Interstitial Lung Disease | Sarcoidosis | Idiopathic Interstitial Pneumonia | Cryptogenic Organizing Pneumonia | Desquamative Interstitial Pneumonia | Respiratory Bronchiolitis Associated Interstitial Lung Disease and other conditions

United States, Germany
Reata, a wholly owned subsidiary of Biogen

Terminated

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Brain Metastases

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

Glioma

United States
Reata, a wholly owned subsidiary of Biogen

Terminated

Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic

Clinical Trials Sponsored by Achillion, a wholly owned subsidiary of Alexion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations